Siberia | Technology & innovation

Scientists offer solution to blood circulation problems

8 May '19
Scientists at the Institute of Biology in the northwestern Russian region of Komi and their colleagues in Tomsk, in Siberia, have developed a pharmacological substance that is likely to become the basis of a new drug candidate to treat blood circulation disorders.

Their product is reported to show antioxidative, hemorrheological, antithrombogenic, neuroprotective and retina-protective activities, thus improving the properties of blood and increasing cerebral blood flow for effective treatment of patients with chronic blood circulation disorders.

Three-year preclinical trials conducted in partnership with the Institute of Pharmacology and Regenerative Medicine in Tomsk have led the team to believe that “there’s no analog in the global pharmaceutical market to match the combination of the new drug candidate’s useful properties.”

Clinical trial phase testing is expected to take between five and seven years.
Publish in Twitter
Write to Facebook
Google Buzz
Write to LiveJournal
Show in MM
Share MK
COMMENT ON THIS STORY
Find Related Content

Locations: Komi; Tomsk

Tags: pharmacological substance (0) / blood circulation disorders (0) /

 

Feature stories

21 May '20
Russian and Italian researchers have developed a...
5 Apr '20
To extend the service life of medical fabric masks—an...
26 Feb '20
A Russian developer has come up with its own...
Search (News archive - 21991)

World of the Future, World of AI

Luc Jones: A Guide to Doing Business in Russia and the CIS Countries
Why Russians Don't Smile
Advertising
Venture_Russia_2019_eng
Advertising
NATT
Advertising
Marchmont News

Latest News

26 May '20
Sberbank, Russia’s largest savings bank, has bought...
25 May '20
Ecwid, a leading provider of social commerce...
22 May '20
The Russian Cabinet is mulling over possible...

Most read stories from last week

25 May '20
Ecwid, a leading provider of social commerce...
26 May '20
Sberbank, Russia’s largest savings bank, has bought...
26 May '20
Interview with Michael Pochepsky, a resident of the...